About
Two day workshop emphasizing research cross-pollination, collaboration, and resource sharing among labs, clinics, and advocacy partners working on curing NUT carcinoma.
Themes
- Novel therapeutics & targets
- Mechanistic epigenetics of {BRD4, BRD3, NSD3}::NUTM1 and related fusions
- In vitro model systems (cell lines and organoids)
- In vivo biology and genetically engineered mouse models
- Shared data, resources, and clinical insights
- Clinical trials and ideas for new trials
Intimate, information-dense workshop capped at ~40 participants.
Schedule
Day 1 • Wed, March 18 Day 2 • Thu, March 19
Wednesday, March 18, 2026
| Time | Speaker | Title |
|---|---|---|
| 9:30–9:50 AM | Alex Rubinsteyn | Opening |
| 9:50–10:10 AM | Jared Weiss | Clinical Progress in NUT Carcinoma |
| 10:10–10:35 AM | Suzanne Vincze | NUT Carcinoma Alliance Update |
| 10:35–10:50 AM | Coffee Break | |
| 10:50–11:30 AM | Christopher French (virtual) | The Achilles Heel of NUT Carcinoma |
| 11:30 AM–12:10 PM | Kyle Eagen | NSD3 Regulates BRD4-NUT-Driven Chromatin Structure and Gene Regulation in NUT Carcinoma |
| 12:10–12:25 PM | Coffee Break | |
| 12:25–1:05 PM | Bin Gu | Genetic Reprogramming by BRD4::NUTM1 In Vivo |
| 1:05–2:05 PM | Lunch | |
| 2:05–2:45 PM | Jeff Jensen | PRAME in NUT Carcinoma: Mechanism and Therapeutics |
| 2:45–3:15 PM | Sarah Bennett | PRAME Directed TCR-T Killing of NUT Carcinoma Cell Lines |
| 3:15–3:55 PM | Alex Rubinsteyn | The Cancer/Testis Landscape of NUT Carcinoma |
| 3:55–4:00 PM | First Day Wrap-Up | |
| 6:30–9:00 PM | Dinner | |
Thursday, March 19, 2026
| Time | Speaker | Title |
|---|---|---|
| 9:30–9:40 AM | Alex Rubinsteyn | Intro to Session on Related Fusion-Driven Cancers |
| Fusion-Driven Cancer Session | ||
| 9:40–10:20 AM | Seth Zimmerman | Convergent Interactomes: How Rhabdomyosarcoma Oncofusions Drive Disease |
| 10:20–11:00 AM | Taylor Durall IV | Characterizing ZEB2 as a Transcriptional Antagonist of PAX3::FOXO1 in Alveolar Rhabdomyosarcoma |
| 11:00–11:15 AM | Coffee Break | |
| 11:15–11:55 AM | Michael Aiduk | Exploiting Oncogenic Hyperactivation and Forced Differentiation to Target CIC::DUX4 Sarcoma |
| Back to NUT Carcinoma | ||
| 11:55 AM–12:35 PM | Jochen Lorch + Rui Yi | Molecular Insights and Clinical Trial Strategies in NUT Carcinoma |
| 12:35–1:35 PM | Lunch | |
| 1:35–2:15 PM | Jiyang Yu + Siarhei Hladyshau | Identifying Hidden Drivers in NUT Carcinoma |
| 2:15–2:30 PM | Coffee Break | |
| 2:30–4:00 PM | All | Closing Discussion — What are the most pressing next steps in NUT carcinoma research? Where are the critical gaps in basic biology, and which therapeutic strategies should be prioritized given the small patient population and limited research community? |
Venue & Travel
The Rizzo Center
150 DuBose Home Lane, Chapel Hill, NC 27517
- Nearest airport: RDU (Raleigh–Durham International)
- Hotel on site; additional Chapel Hill options nearby
- Parking & directions: see venue website and on-site signage
Hosts & Sponsors
Hosted by: The Personalized Immunotherapy Research Lab (PIRL) at UNC
Sponsor: NUT Carcinoma Alliance